HCW Biologics (HCWB) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Redhill Biopharma is the larger company by market cap ($2.5 million vs $2.4 million), about 1.1 times the size. Redhill Biopharma converts more of its revenue into profit, with a net margin of -102.8% versus -14677.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | RDHL |
|---|---|---|
| Share price | $0.7491 | $0.281 |
| Market cap | $2.35M | $2.50M |
| 1-day change | +1.90% | -13.08% |
| Forward P/E | — | 9.37 |
| EPS (TTM) | $-9.09 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.23K | $8.04M |
| Revenue growth (YoY) | -97.89% | +23.17% |
| Net income (latest FY) | $-7.96M | $-8.27M |
| Gross margin | 20.00% | 60.31% |
| Operating margin | -24270.74% | -181.69% |
| Net margin | -14677.14% | -102.80% |
| 52-week high | $23.94 | $1.60 |
| 52-week low | $0.70 | $0.281 |
| Distance from 52-week high | -96.87% | -82.44% |
| Analyst consensus | buy | — |
| Avg. price target upside | +6307.69% | — |
| Average volume | 379.38K | 2.08M |
| Shares outstanding | 3.14M | 8.89M |
| Employees | 35 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Redhill Biopharma is more profitable, keeping -102.8 cents of every revenue dollar as net income versus -14677.1 cents for HCW Biologics.
- Redhill Biopharma grew revenue faster in its latest fiscal year (+23.17% vs -97.89%).
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
HCWB vs RDHL FAQ
Which is bigger, HCW Biologics or Redhill Biopharma?
Redhill Biopharma (RDHL) is larger, with a market capitalization of $2.50M compared with $2.35M for HCW Biologics (HCWB).
Are HCW Biologics and Redhill Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.